Submit Your Feeds

Business News • PR NewsWire • PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy

PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy
PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy

SOUTH PLAINFIELD, N.J., Nov. 25, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the United States Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for risdiplam (RG7916) for the treatment of spinal muscular...

View More : https://www.prnewswire.com:443/news-releases/ptc-therapeutics-announces-fda-grants-priority-review-to-risdiplam-for-the-...
Releted News by prnewswire
The Uber of Car Tires Launches
REALOGY HOLDINGS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Realogy Holdings Corp. - RLGY
PTC Therapeutics Announces FDA Grants Priority Review to Risdiplam for the Treatment of Spinal Muscular Atrophy
Jacobs Reports Fiscal Fourth Quarter Earnings
Plug and Play ADGM Hosts Their Second Annual Demo Day Featuring Over 20 Fintech, Traveltech and Healthtech Startups
Home Sitemap Contact Us
© businessNewsNewsNews.com